Zurich (awp) – The Chinese drug regulator has approved a new route of administration of the antifungal Cresemba (isavuconazole) in the Middle Kingdom. The treatment for adult patients with invasive aspergillosis and invasive mucormycosis, which was already authorized in oral form, will now be available in intravenous mode.
Formally, the National Medical Products Administration (NMPA) grants distribution authorization to Pfizer, Basilea’s distribution partner in China, the Basel laboratory wrote in a press release on Friday.
In its oral form, the drug had been approved in China against invasive aspergillosis in January 2022.
rq/jh